eISSN: 2299-0046
ISSN: 1642-395X
Advances in Dermatology and Allergology/Postępy Dermatologii i Alergologii
Current issue Archive Manuscripts accepted About the journal Abstracting and indexing Subscription Contact Instructions for authors
SCImago Journal & Country Rank
1/2019
vol. 36
 
Share:
Share:
more
 
 
abstract:
Original paper

Does omalizumab treatment affect serum dehydroepiandrosterone sulphate levels in chronic idiopathic urticaria?

Atıl Avcı, Deniz Avcı, Ragip Ertas, Mustafa Atasoy, Cigdem Karakukcu, Efşan Yontar, Yilmaz Ulas, Kemal Ozyurt

Adv Dermatol Allergol 2019; XXXVI (1): 92-97
Online publish date: 2019/02/22
View full text
Get citation
ENW
EndNote
BIB
JabRef, Mendeley
RIS
Papers, Reference Manager, RefWorks, Zotero
AMA
APA
Chicago
Harvard
MLA
Vancouver
 
Introduction
It is known that serum dehydroepiandrosterone sulphate (DHEA-S) levels are low in patients with chronic idiopathic urticaria.

Aim
In the study, the effect of the drug on the DHEA-S serum levels and its correlation with the remission and relapse times of the disease was investigated.

Material and methods
Fifty-seven patients with chronic idiopathic urticaria who were referred to our hospital and 20 healthy volunteers were included in the study. A subcutaneous injection of 300 mg omalizumab was administered to the patient group. Drug injections at this dose were completed (6 injections in total, one per month). Relations between serum DHEA-S levels and relapse rates, treatment response and remission duration of the patients and control group were investigated in the groups. 

Results
Median DHEA-S value before treatment was 116.3 (21.5–448.7) µg/dl; the median DHEA-S value measured after 3 months was 98.4 (10.0–410.0) µg/dl (p = 0.003). The median DHEA-S value before treatment was 123.1 (21.5–299.6) µg/dl when the initial and 3-month DHEA-S levels of the 34 complete remission patients were compared; after 3 months the value was 100.4 (23.1–301.9) µg/dl (p = 0.021).

Conclusions
This is the first study to investigate the effect of omalizumab treatment on DHEA-S levels in the treatment of chronic urticaria according to our literature review. The DHEA-S levels were found to be significantly lower after omalizumab therapy but not related to remission and relapse times.

keywords:

omalizumab, chronic idiopathic urticaria, inflammation, dehydroepiandrosterone sulphate

references:
Schocket AL. Chronic urticaria: pathophysiology and etiology, or the what and why. Allergy Asthma Proc 2006; 27: 90-5.
Bertinotti L, Miniati I, Cerinic MM. Angioedema and systemic sclerosis. A review of the literature. Scand J Rheumatol 2002; 31: 178-80.
Ertaş R, Özyurt K, Yıldız S, et al. Adverse reaction to omalizumab in patients with chronic urticaria: flare up or ineffectiveness? Iran J Allergy Asthma Immunol 2016; 15: 82-6.
Gibbs CJ, Coutts II, Lock R, et al. Premenstrual exacerbation of asthma. Thorax 1984; 39: 833-6.
Yell JA, Burge SM. The effect of hormonal changes on cutaneous disease in lupus erythematosus. Br J Dermatol 1993; 129: 18-22.
Kasperska-Zajac A. Does dehydroepiandrosterone influence the expression of urticaria? A mini review. Inflammation 2011; 34: 362-6.
Barry NN, McGuire JL, van Vollenhoven RF. Dehydroepiandrosterone in systemic lupus erythematosus: relationship between dosage, serum levels, and clinical response. J Rheumatol 1998; 25: 2352-6.
Dillon JS. Dehydroepiandrosterone, dehydroepiandrosterone sulfate and related steroids: their role in inflammatory, allergic and immunological disorders. Curr Drug Targets Inflamm Allergy 2005; 4: 377-85.
Mittman RJ, Bernstein DI, Steinberg DR, et al. Progesterone-responsive urticaria and eosinophilia. J Allergy Clin Immunol 1989; 84: 304-10.
Lucas JA, Ahmed SA, Casey ML, MacDonald PC. Prevention of autoantibody formation and prolonged survival in New Zealand Black/New Zealand White F1 mice fed dehydroisoandrosterone. J Clin Invest 1985; 75: 2091-3.
Daynes RA, Dudley DJ, Araneo BA. Regulation of murine lymphokine production in vivo II. Dehydroepiandrosterone is a natural enhancer of interleukin 2 synthesis by helper T cells. Eur J Immunol 1990; 20: 793-802.
Kroboth PD, Salek FS, Pittenger AL, et al. DHEA and DHEA-S: a review. J Clin Pharmacol 1999; 39: 327-48.
Platts-mills TAE, Erwin E, Heymann P, Woodfolk J. Is the hygiene hypothesis still a viable explanation for the increased prevalence of asthma? Allergy 2005; 60: 25-31.
Ford ES. The epidemiology of obesity and asthma. J Allergy Clin Immunol 2005; 115: 897-909.
Barry NN, McGuire JL, van Vollenhoven RF. Dehydroepiandrosterone in systemic lupus erythematosus: relationship between dosage, serum levels, and clinical response. J Rheumatol 1998; 25: 2352-6.
Schwartz KE. Autoimmunity, dehydroepiandrosterone (DHEA), and stress. J Adoles Health 2002; 30S: 37-43.
Straub RH, Schuld A, Mullington J, et al. The endotoxin-induced increase of cytokines is followed by an increase of cortisol relative to dehydroepiandrosterone (DHEA) in healthy male subjects. J Endocrinol 2002; 175: 467-74.
Kasperska-Zajac A, Brzoza Z, Badura-Brzoza K, et al. Does the dehydroepiandrosterone sulphate decline in chronic urticaria result from psychological distress? Allergy 2007; 62 (Suppl. 83): poster 1640. p. 564.
Hidvegi T, Feher GK, Feher T, et al. Inhibition of the complement activation by an adrenal androgen, dehydroepiandrosterone. Complement 1984; 1: 201-6.
Fernández-Antón Martínez MC, Leis-Dosil V, Alfageme-Roldán F, Paravisini A. Omalizumab for the treatment of atopic dermatitis. Actas Dermosifiliogr 2012; 103: 624-8.
Ferrer M, Gamboa P, Sanz ML, et al. Omalizumab is effective in non autoimmuneurticaria. J Allergy Clin Immunol 2011; 127: 1300-2.
Ivyanskiy I, Sand C, Francis ST. Omalizumab for chronicurticaria: a case series and overview of the literature. Case Rep Dermatol 2012; 4: 19-26.
Maurer M, Altrichter S, Bieber T, et al. Efficacy and safety of omalizumab in patients with chronic urticaria who exhibit IgE against thyroperoxidase. J Allergy Clin Immunol 2011; 128: 202-9.
Pawlikowski M. Adrenal cortex – the next biological clock. Neuro Endocrinol Lett 2005; 26: 193-5.
Rook GA, Hernandez-Pando R, Lightman SL. Hormones, peripherally activated prohormones and regulation of the Th1/Th2 balance. Immunol Today 1994; 15: 301-3.
Panconesi E, Hautmann G. Stress, stigmatization and psychosomatic purpuras. Int Angiol 1995; 14: 130-7.
Kumar SA, Martin BL. Urticaria and angioedema: diagnostic and treatment considerations. J Am Osteopathic Assoc 1999; 99 (3 Suppl): S1-4.
Baiardini I, Giardini A, Pasquali M, et al. Quality of life and patients’ satisfaction in chronic urticaria and respiratory allergy. Allergy 2003; 58: 621-3.
Quick links
© 2019 Termedia Sp. z o.o. All rights reserved.
Developed by Bentus.
PayU - płatności internetowe